Real-time Estimate Cboe BZX 03:54:14 2024-02-21 pm EST 5-day change 1st Jan Change
180.2 USD -0.26% Intraday chart for ResMed, Inc. -0.41% +4.53%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Australia shares slip as biotech firm CSL slumps on failed drug trial (Feb 12) RE
Powell, the paper tiger Our Logo
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking... Our Logo
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Oppenheimer Raises ResMed Price Target to $185 From $175, Maintains Outperform Rating MT
RBC Lifts Price Target on ResMed to $182 From $181, Cites 'Solid' Fiscal Q2 Results, Keeps Sector Perform Rating MT
ResMed Fiscal Q2 Non-GAAP Earnings, Revenue Increase; Shares Rise Premarket MT
ResMed Posts Lower Fiscal Q2 Profit; Shares Up 7% MT
ResMed Declares Q4 Dividend; Shares Jump 7% MT
ResMed beats estimates on strong sleep apnea device sales RE
ResMed Resumes Share Buyback Program With $50 Million of Repurchases in Fiscal Q2 MT
ResMed Keeps Quarterly Cash Dividend at $0.48 a Share, Payable March 14 to Holders of Record Feb. 8 MT
ResMed Fiscal Q2 Non-GAAP Earnings, Revenue Increases; Shares Jump After-Hours MT
ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024 CI
Transcript : ResMed Inc., Q2 2024 Earnings Call, Jan 24, 2024
Tranche Update on ResMed Inc.'s Equity Buyback Plan announced on February 27, 2014. CI
ResMed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Australia's oldest listed investment firm says lithium stocks turning attractive RE
RBC Cuts Price Target on ResMed to $181 From $200, Keeps Sector Perform Rating MT
ResMed says its masks to remain on market despite FDA classification RE
Noctrix Health, Inc. announced that it has received $39.999991 million in funding from Sectoral Asset Management Inc., Angelini Ventures, ResMed Inc., Asahi Kasei Corporate Venture Capital, OrbiMed Advisors LLC, Treo Ventures, LLC CI
Global markets live: Burberry, Bank of America, JPMorgan, Wells Fargo, Tesla... Our Logo
Chart ResMed, Inc.
More charts
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows: - medical devices (50.4%); - masks (37.9%); - software as a service (11.7%). At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia. The United States accounts for 61.4% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
180.7 USD
Average target price
205 USD
Spread / Average Target
+13.46%
Consensus
  1. Stock
  2. Equities
  3. Stock ResMed, Inc. - Nyse
  4. News ResMed, Inc.
  5. Resmed Insider Sold Shares Worth $863,281, According to a Recent SEC Filing
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer